No Detail Found!

Regadenoson myocardial perfusion scintigraphy: a single centre experience

Author(s)
Muhammad Adil Nuclear Medical Centre, Armed Forces Institute of Pathology,Rawalpindi-,Pakistan
Zaigham Salim Dar Nuclear Medical Centre, Armed Forces Institute of Pathology,Rawalpindi-,Pakistan
Shahbaz Afsar Khan Combined Military Hospital Abbottabad-,,Pakistan
Fida Hussain Nuclear Medical Centre, Armed Forces Institute of Pathology,Rawalpindi-,Pakistan
Asad Malik Nuclear Medical Centre, Armed Forces Institute of Pathology,Rawalpindi-,Pakistan
Husnain Saleem Nuclear Medical Centre, Armed Forces Institute of Pathology,Rawalpindi-,Pakistan
Abstract
Background: Regadenoson is highly selective A2A adenosine receptors agonist used for stress myocardial perfusion scintigraphy. This study presents our initial experience utilizing Regadenoson as a myocardial perfusion stress agent, aimed to assess the safety of Regadenoson for stress myocardial perfusion scintigraphy. Methods: Following Institutional Ethical Review Borad approval, adult patients presenting for myocardial stress perfusion scintigraphy were included using non-probability consecutive sampling. Exclusions included second or third-degree AV block, unstable angina, recent myocardial infarction, severe hypotension, or significant heart failure. Demographic data, co-morbidities, vitals, and adverse events were recorded. Results: Sixty-three patients were included, predominantly male (63.5%), with a mean age of 56.81±12.95 years. Hyperlipidaemia was the most common co-morbidity (47.6%). Systolic and diastolic blood pressure decreased acutely but normalised by 60 minutes. No serious adverse effects occurred, though transient ST segment depression was noted in 8.3% of patients. The most common adverse effects were dyspnoea (23.8%) and headache (21.4%). Conclusion: Regadenoson is associated with transient haemodynamic changes and non-serious transient adverse effects.
Publication Details
Page(s) 630-635
Published Journal: Journal of Ayub Medical College, Volume: 36, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Coronary artery disease, Myocardial perfusion imaging, Regadenoson
References
Vos T,Lim SS,Abbafati C,Abbas KM,Abbasi M,Abbasifard M .2020 .-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396(10258) : 1204-22.
Jafar TH,Qadri Z,Chaturvedi N. .2008 .Coronary artery disease epidemic in Pakistan: more electrocardiographic evidence of ischemia in women than in men. Heart, 94(4) : 408-13.
Dodani S,MacLean DD,LaPorte RE,Joffres M. Distribution .2005 .and determinants of coronary artery disease in an urban Pakistani setting. Ethn Dis, 15(3) : 429-35.
Volgman AS,Palaniappan LS,Aggarwal NT,Gupta M,Khandelwal A,Krishnan AV .2018 .Atherosclerotic cardiovascular disease in South Asians in the United States: Epidemiology, risk factors, and treatments: A scientific statement from the American heart association. Circulation, 138(1) : e1-34.
Shahjehan RD,Bhutta BS .2024 .Coronary artery disease. Treasure Island, : .
Lan WC,Chen YH,Liu SH .2013 .Non-invasive imaging modalities for the diagnosis of coronary artery disease: The present and the future. Tzu Chi Med J, 25(4) : 206-12.
Boschi A,Uccelli L,Marvelli L,Cittanti C,Giganti M,Martini P. Technetium M . .-99m radiopharmaceuticals for ideal myocardial perfusion imaging: Lost and found opportunities. , : .
Molecules .2022 .. , 27(4) : 1188.
molecules27041188 Mann A,Williams J . .Considerations for stress testing performed in conjunction with myocardial perfusion imaging. , : .
.2020 .. J Nucl Med Technol, 48(2) : 114-21.
Saab R,Hage FG .2017 .Vasodilator stress agents for myocardial perfusion imaging. J Nucl Cardiol, 24 : 434-8.
.2021 .Regadenoson stress testing: A comprehensive review with a focused update. Cureus, 13(1) : e12940.
Koutsikos J,Angelidis G,Zafeirakis A,Mamarelis I,Vogiatzis M,Ilia E .2017 .Performance and safety profile of regadenoson myocardial perfusion imaging: first experience in Greece. Hell J Nucl Med, 20(3) : 232-6.
Pape M,Zacho HD,Aarøe J,Eggert Jensen S,Petersen LJ .2016 .Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience. Scand Cardiovasc J, 50(3) : 180-6.
Sakala R,Summers B,Lundie M. .2023 .Regadenoson compared to other pharmacological stressors used in myocardial perfusion imaging (MPI) at the department of nuclear medicine at a tertiary academic hospital in Gauteng, South Africa. World J Nucl Med, 22(2) : 38.
Keller M .2020 .Pharmacological stress test for myocardial ischemia when Adenosine is contraindicated: prospective documentation of side effects in over 700 patients with COPD or bronchial asthma. Eur Heart J, 41(Suppl) : ehaa282-946.
Salgado-Garcia C,Jimenez-Heffernan A,Ramos-Font C,Lopez-Martin J,Sanchez-de-Mora E,Aroui T .2016 .Safety of regadenoson in patients with severe chronic obstructive pulmonary disease. Rev Esp Med Nucl Imagen Mol, 35(5) : 283-6.
Ananthasubramaniam K,Weiss R,McNutt B,Klauke B,Feaheny K,Bukofzer S K .2012 .A randomized, double-blind, placebocontrolled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol, 19(2) : 319-29.
AlJaroudi WA,Alraies MC,Cerquiera MD,Jaber WA .2013 .Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response. Eur J Nucl Med Mol Imaging, 40(3) : 341-8.
0

Citations

0

Downloads

97

Views